- Thursday, 30 July 2015
- AstraZeneca PLC H1 2015 results “We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas."
- Monday, 27 July 2015
- AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine.
- Wednesday, 22 July 2015
- AstraZeneca provides update on selumetinib in uveal melanoma AstraZeneca provides update on selumetinib in uveal melanoma
- Friday, 17 July 2015
- AstraZeneca completes agreement with Tillotts Pharma for Entocort AstraZeneca today announced that it has completed its agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort ® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis.
- Thursday, 16 July 2015
- AstraZeneca enters option agreement with Kyowa Hakko Kirin for commercialisation of benralizumab in Japan AstraZeneca today announced that it has entered an agreement with Kyowa Hakko Kirin Co. Ltd. (Kyowa Hakko Kirin) for an exclusive option to commercialise benralizumab for asthma and chronic obstructive pulmonary disease (COPD) in Japan.
- Monday, 13 July 2015
- IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved IRESSA (gefitinib) tablets, 250mg once daily, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.
- Thursday, 9 July 2015
- AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma for Entocort AstraZeneca announced today that it has entered into an agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis. Entocort is currently available in over 40 countries, with total product sales of $53 million outside the US in 2014. A regulatory submission for Entocort in Japan is anticipated in the coming months.
- Tuesday, 16 June 2015
- AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT AstraZeneca today announced that Pam P. Cheng has joined the Company as Executive Vice President, Operations and IT. Pam will succeed David Smith, who is retiring after nearly ten years with AstraZeneca.
- Thursday, 11 June 2015
- AstraZeneca reveals findings of archaeological dig as build gets underway at Cambridge Biomedical Campus AstraZeneca today announced the findings of archaeological excavations on the Cambridge Biomedical Campus, which will be home to the Company’s new, purpose-built global R&D centre and corporate headquarters from the end of 2016.
- Monday, 8 June 2015
- New real-world data analysis finds no evidence of increased risk of hospitalisation for heart failure with saxagliptin compared with sitagliptin AstraZeneca today announced results from an observational, retrospective study which found no evidence of increased risk of hospitalisation for heart failure (hHF) with saxagliptin, compared with sitagliptin, both of which are dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients with type 2 diabetes. A similar finding was obtained when comparing the overall DPP-4 class to sulfonylureas. The analysis included patients with and without prior cardiovascular disease (CVD), and among those patients without prior cardiovascular disease (CVD), DPP-4 treatment was associated with statistically significant lower risk for hHF compared to treatment with sulfonylureas.
Soriot: Reaffirm confidence in meeting revenue targets30 Jul
Fast pace of progress in oncology – 2 approvals, 3 regulatory submissions and 6 NMEs in late stage or under regulatory review30 Jul
Pascal Soriot: We made good progress in the period, delivering a robust underlying business performance30 Jul